Nationwide Fund Advisors’s Cellular Biomedicine Group, Inc. CBMG Stock Holding History

Nationwide Fund Advisors’s Portfolio CBMG Stock Details CBMG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-7,084	Closed	-$84K	–	3296
2017 Q1	$84K	Sell	7,084 -1,065	-13%	-$12.9K	﹤0.01%	2889
2016 Q4	$107K	Buy	8,149 +906	+13%	+$12.1K	﹤0.01%	2857
2016 Q3	$105K	Hold	7,243	–	–	﹤0.01%	2873
2016 Q2	$87K	Buy	7,243 +892	+14%	+$14.3K	﹤0.01%	2966
2016 Q1	$118K	Hold	6,351	–	–	﹤0.01%	2752
2015 Q4	$136K	Hold	6,351	–	–	﹤0.01%	2730
2015 Q3	$108K	Hold	6,351	–	–	﹤0.01%	2870
2015 Q2	$238K	Buy	+6,351	New	+$205K	﹤0.01%	2620

Other funds holding CBMG

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Paloma Partners Greenwich, Connecticut $510M AUM 286.05% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

LMR Partners London, United Kingdom $45.4B AUM 60.68% 1-Year Est. Return

Nationwide Fund Advisors's CBMG Position: Q2 2017 in Review

Nationwide Fund Advisors sold out of Cellular Biomedicine Group, Inc. (CBMG) in Q2 2017, closing a stake of 7,084 shares — an estimated $84K sold.

Nationwide Fund Advisors first reported a position in CBMG in Q2 2015 and held it in 8 quarters. The position peaked at $238K in Q2 2015. 24 funds tracked by Wall St. Rank hold CBMG as of Q2 2017.

Nationwide Fund Advisors reported no remaining Cellular Biomedicine Group, Inc. position as of Q2 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 7,084 Cellular Biomedicine Group, Inc. shares in Q2 2017, an estimated $84K.
Nationwide Fund Advisors first reported a position in Cellular Biomedicine Group, Inc. in Q2 2015 and held it in 8 quarters.
Nationwide Fund Advisors's Cellular Biomedicine Group, Inc. position peaked at $238K in Q2 2015.
24 funds tracked by Wall St. Rank held Cellular Biomedicine Group, Inc. as of Q2 2017.

Based on Nationwide Fund Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.